Number of Participants With Maximum Urinalysis Change From Baseline-Part 2
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers · Source last updated 2020-03-16
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
Urine samples were collected for the analysis of following urine parameters: pH, glucose, protein, blood, ketones, specific gravity, erythrocytes and leukocytes. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Only parameters and time points with non-zero values for any increase have been presented.
Analysis population: All Treated Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles).
Groups in this outcome
Part 2: Participants With NMC
Participants with NUT Midline Carcinoma (NMC) were administered continuous once daily oral dose of 75 mg GSK525762.
Part 2: Participants With SCLC
Participants with small cell lung cancer(SCLC) were administered continuous once daily oral dose of 75 mg GSK525762.
Part 2: Participants With CRPC
Participants with Castrate-Resistant Prostate Cancer (CRPC) were administered continuous once daily oral dose of 75 mg GSK525762.
Part 2: Participants With TNBC
Participants with Triple Negative Breast Cancer (TNBC) were administered continuous once daily oral dose of 75 mg GSK525762.
Part 2: Participants With ER+BC
Participants with estrogen receptor positive breast cancer (ER+BC) were administered continuous once daily oral dose of 75 mg GSK525762.
Part 2: Participants With GIST
Participants with Gastrointestinal Stromal Tumor (GIST) were administered continuous once daily oral dose of 75 mg GSK525762.
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
Group
Source count
Part 2: Participants With NMC
12
Part 2: Participants With SCLC
14
Part 2: Participants With CRPC
23
Part 2: Participants With TNBC
19
Part 2: Participants With ER+BC
21
Part 2: Participants With GIST
13
Reported measurements
Granular cast;Week5;n=0,2,2,1,3,0
Analysis denominator · Participants
Group
Source count
Part 2: Participants With NMC
0
Part 2: Participants With SCLC
2
Part 2: Participants With CRPC
2
Part 2: Participants With TNBC
1
Part 2: Participants With ER+BC
3
Part 2: Participants With GIST
0
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 2: Participants With SCLC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With CRPC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With TNBC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With ER+BC
1
Not reported
Not reported
Not reported
Not reported
Granular cast;disc/prog;n=1,2,6,3,4,0
Analysis denominator · Participants
Group
Source count
Part 2: Participants With NMC
1
Part 2: Participants With SCLC
2
Part 2: Participants With CRPC
6
Part 2: Participants With TNBC
3
Part 2: Participants With ER+BC
4
Part 2: Participants With GIST
0
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 2: Participants With NMC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With SCLC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With CRPC
2
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With TNBC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With ER+BC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With GIST
0
Not reported
Not reported
Not reported
Not reported
Hyaline cast;Week5;n=1,2,2,2,4,0
Analysis denominator · Participants
Group
Source count
Part 2: Participants With NMC
1
Part 2: Participants With SCLC
2
Part 2: Participants With CRPC
2
Part 2: Participants With TNBC
2
Part 2: Participants With ER+BC
4
Part 2: Participants With GIST
0
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 2: Participants With NMC
1
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With SCLC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With CRPC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With TNBC
1
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With ER+BC
1
Not reported
Not reported
Not reported
Not reported
Hyaline cast;Week9;n=0,0,1,2,1,1
Analysis denominator · Participants
Group
Source count
Part 2: Participants With NMC
0
Part 2: Participants With SCLC
0
Part 2: Participants With CRPC
1
Part 2: Participants With TNBC
2
Part 2: Participants With ER+BC
1
Part 2: Participants With GIST
1
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 2: Participants With CRPC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With TNBC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With ER+BC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With GIST
1
Not reported
Not reported
Not reported
Not reported
Hyaline cast;Week13;n=1,1,0,0,0,0
Analysis denominator · Participants
Group
Source count
Part 2: Participants With NMC
1
Part 2: Participants With SCLC
1
Part 2: Participants With CRPC
0
Part 2: Participants With TNBC
0
Part 2: Participants With ER+BC
0
Part 2: Participants With GIST
0
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 2: Participants With NMC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With SCLC
1
Not reported
Not reported
Not reported
Not reported
Hyaline cast;disc/prog;n=1,2,6,3,4,0
Analysis denominator · Participants
Group
Source count
Part 2: Participants With NMC
1
Part 2: Participants With SCLC
2
Part 2: Participants With CRPC
6
Part 2: Participants With TNBC
3
Part 2: Participants With ER+BC
4
Part 2: Participants With GIST
0
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 2: Participants With NMC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With SCLC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With CRPC
2
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With TNBC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With ER+BC
0
Not reported
Not reported
Not reported
Not reported
Glucose;Week 5;n=8,7,18,12,14,8
Analysis denominator · Participants
Group
Source count
Part 2: Participants With NMC
8
Part 2: Participants With SCLC
7
Part 2: Participants With CRPC
18
Part 2: Participants With TNBC
12
Part 2: Participants With ER+BC
14
Part 2: Participants With GIST
8
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 2: Participants With NMC
1
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With SCLC
2
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With CRPC
2
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With TNBC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With ER+BC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With GIST
1
Not reported
Not reported
Not reported
Not reported
Glucose;Week9;n=8,3,12,3,6,5
Analysis denominator · Participants
Group
Source count
Part 2: Participants With NMC
8
Part 2: Participants With SCLC
3
Part 2: Participants With CRPC
12
Part 2: Participants With TNBC
3
Part 2: Participants With ER+BC
6
Part 2: Participants With GIST
5
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 2: Participants With NMC
2
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With SCLC
1
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With CRPC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With TNBC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With ER+BC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With GIST
0
Not reported
Not reported
Not reported
Not reported
Glucose;Week13;n=7,2,6,1,2,2
Analysis denominator · Participants
Group
Source count
Part 2: Participants With NMC
7
Part 2: Participants With SCLC
2
Part 2: Participants With CRPC
6
Part 2: Participants With TNBC
1
Part 2: Participants With ER+BC
2
Part 2: Participants With GIST
2
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 2: Participants With NMC
2
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With SCLC
1
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With CRPC
1
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With TNBC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With ER+BC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With GIST
0
Not reported
Not reported
Not reported
Not reported
Glucose;Week37;n=3,0,1,0,0,0
Analysis denominator · Participants
Group
Source count
Part 2: Participants With NMC
3
Part 2: Participants With SCLC
0
Part 2: Participants With CRPC
1
Part 2: Participants With TNBC
0
Part 2: Participants With ER+BC
0
Part 2: Participants With GIST
0
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 2: Participants With NMC
1
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With CRPC
0
Not reported
Not reported
Not reported
Not reported
Glucose;Week49;n=1,0,1,0,0,0
Analysis denominator · Participants
Group
Source count
Part 2: Participants With NMC
1
Part 2: Participants With SCLC
0
Part 2: Participants With CRPC
1
Part 2: Participants With TNBC
0
Part 2: Participants With ER+BC
0
Part 2: Participants With GIST
0
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 2: Participants With NMC
1
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With CRPC
0
Not reported
Not reported
Not reported
Not reported
Glucose;Week73;n=1,0,0,0,0,0
Analysis denominator · Participants
Group
Source count
Part 2: Participants With NMC
1
Part 2: Participants With SCLC
0
Part 2: Participants With CRPC
0
Part 2: Participants With TNBC
0
Part 2: Participants With ER+BC
0
Part 2: Participants With GIST
0
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 2: Participants With NMC
1
Not reported
Not reported
Not reported
Not reported
Glucose;Week85;n=1,0,0,0,0,0
Analysis denominator · Participants
Group
Source count
Part 2: Participants With NMC
1
Part 2: Participants With SCLC
0
Part 2: Participants With CRPC
0
Part 2: Participants With TNBC
0
Part 2: Participants With ER+BC
0
Part 2: Participants With GIST
0
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 2: Participants With NMC
1
Not reported
Not reported
Not reported
Not reported
Glucose;disc/prog;n=3,6,16,12,12,5
Analysis denominator · Participants
Group
Source count
Part 2: Participants With NMC
3
Part 2: Participants With SCLC
6
Part 2: Participants With CRPC
16
Part 2: Participants With TNBC
12
Part 2: Participants With ER+BC
12
Part 2: Participants With GIST
5
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 2: Participants With NMC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With SCLC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With CRPC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With TNBC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With ER+BC
1
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With GIST
0
Not reported
Not reported
Not reported
Not reported
Ketones;Week5;n=8,7,18,12,14,8
Analysis denominator · Participants
Group
Source count
Part 2: Participants With NMC
8
Part 2: Participants With SCLC
7
Part 2: Participants With CRPC
18
Part 2: Participants With TNBC
12
Part 2: Participants With ER+BC
14
Part 2: Participants With GIST
8
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 2: Participants With NMC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With SCLC
1
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With CRPC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With TNBC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With ER+BC
1
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With GIST
0
Not reported
Not reported
Not reported
Not reported
Ketones;Week9;n=8,3,12,3,6,5
Analysis denominator · Participants
Group
Source count
Part 2: Participants With NMC
8
Part 2: Participants With SCLC
3
Part 2: Participants With CRPC
12
Part 2: Participants With TNBC
3
Part 2: Participants With ER+BC
6
Part 2: Participants With GIST
5
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 2: Participants With NMC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With SCLC
1
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With CRPC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With TNBC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With ER+BC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With GIST
0
Not reported
Not reported
Not reported
Not reported
Ketones;disc/prog;n=3,6,16,12,12,5
Analysis denominator · Participants
Group
Source count
Part 2: Participants With NMC
3
Part 2: Participants With SCLC
6
Part 2: Participants With CRPC
16
Part 2: Participants With TNBC
12
Part 2: Participants With ER+BC
12
Part 2: Participants With GIST
5
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 2: Participants With NMC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With SCLC
1
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With CRPC
2
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With TNBC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With ER+BC
1
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With GIST
0
Not reported
Not reported
Not reported
Not reported
Occult blood;Week5;n=8,7,18,12,14,8
Analysis denominator · Participants
Group
Source count
Part 2: Participants With NMC
8
Part 2: Participants With SCLC
7
Part 2: Participants With CRPC
18
Part 2: Participants With TNBC
12
Part 2: Participants With ER+BC
14
Part 2: Participants With GIST
8
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 2: Participants With NMC
1
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With SCLC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With CRPC
5
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With TNBC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With ER+BC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With GIST
0
Not reported
Not reported
Not reported
Not reported
Occult blood;Week9;n=8,3,12,3,6,5
Analysis denominator · Participants
Group
Source count
Part 2: Participants With NMC
8
Part 2: Participants With SCLC
3
Part 2: Participants With CRPC
12
Part 2: Participants With TNBC
3
Part 2: Participants With ER+BC
6
Part 2: Participants With GIST
5
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 2: Participants With NMC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With SCLC
1
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With CRPC
5
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With TNBC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With ER+BC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With GIST
0
Not reported
Not reported
Not reported
Not reported
Occult blood;Week13;n=7,2,6,1,2,2
Analysis denominator · Participants
Group
Source count
Part 2: Participants With NMC
7
Part 2: Participants With SCLC
2
Part 2: Participants With CRPC
6
Part 2: Participants With TNBC
1
Part 2: Participants With ER+BC
2
Part 2: Participants With GIST
2
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 2: Participants With NMC
1
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With SCLC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With CRPC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With TNBC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With ER+BC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With GIST
0
Not reported
Not reported
Not reported
Not reported
Occult blood;Week25;n=2,0,3,0,0,0
Analysis denominator · Participants
Group
Source count
Part 2: Participants With NMC
2
Part 2: Participants With SCLC
0
Part 2: Participants With CRPC
3
Part 2: Participants With TNBC
0
Part 2: Participants With ER+BC
0
Part 2: Participants With GIST
0
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 2: Participants With NMC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With CRPC
1
Not reported
Not reported
Not reported
Not reported
Occult blood;Week37;n=3,0,1,0,0,0
Analysis denominator · Participants
Group
Source count
Part 2: Participants With NMC
3
Part 2: Participants With SCLC
0
Part 2: Participants With CRPC
1
Part 2: Participants With TNBC
0
Part 2: Participants With ER+BC
0
Part 2: Participants With GIST
0
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 2: Participants With NMC
1
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With CRPC
0
Not reported
Not reported
Not reported
Not reported
Occult blood;disc/prog;n=3,6,16,12,12,5
Analysis denominator · Participants
Group
Source count
Part 2: Participants With NMC
3
Part 2: Participants With SCLC
6
Part 2: Participants With CRPC
16
Part 2: Participants With TNBC
12
Part 2: Participants With ER+BC
12
Part 2: Participants With GIST
5
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 2: Participants With NMC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With SCLC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With CRPC
8
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With TNBC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With ER+BC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With GIST
0
Not reported
Not reported
Not reported
Not reported
pH;Week5;n=8,7,18,12,14,8
Analysis denominator · Participants
Group
Source count
Part 2: Participants With NMC
8
Part 2: Participants With SCLC
7
Part 2: Participants With CRPC
18
Part 2: Participants With TNBC
12
Part 2: Participants With ER+BC
14
Part 2: Participants With GIST
8
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 2: Participants With NMC
6
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With SCLC
3
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With CRPC
8
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With TNBC
3
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With ER+BC
6
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With GIST
3
Not reported
Not reported
Not reported
Not reported
pH;Week9;n=8,3,12,3,6,5
Analysis denominator · Participants
Group
Source count
Part 2: Participants With NMC
8
Part 2: Participants With SCLC
3
Part 2: Participants With CRPC
12
Part 2: Participants With TNBC
3
Part 2: Participants With ER+BC
6
Part 2: Participants With GIST
5
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 2: Participants With NMC
5
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With SCLC
1
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With CRPC
7
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With TNBC
2
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With ER+BC
4
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With GIST
2
Not reported
Not reported
Not reported
Not reported
pH;Week13;n=7,2,6,1,2,2
Analysis denominator · Participants
Group
Source count
Part 2: Participants With NMC
7
Part 2: Participants With SCLC
2
Part 2: Participants With CRPC
6
Part 2: Participants With TNBC
1
Part 2: Participants With ER+BC
2
Part 2: Participants With GIST
2
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 2: Participants With NMC
2
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With SCLC
1
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With CRPC
3
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With TNBC
1
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With ER+BC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With GIST
1
Not reported
Not reported
Not reported
Not reported
pH;Week25;n=2,0,3,0,0,0
Analysis denominator · Participants
Group
Source count
Part 2: Participants With NMC
2
Part 2: Participants With SCLC
0
Part 2: Participants With CRPC
3
Part 2: Participants With TNBC
0
Part 2: Participants With ER+BC
0
Part 2: Participants With GIST
0
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 2: Participants With NMC
1
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With CRPC
1
Not reported
Not reported
Not reported
Not reported
pH;Week37;n=3,0,1,0,0,0
Analysis denominator · Participants
Group
Source count
Part 2: Participants With NMC
3
Part 2: Participants With SCLC
0
Part 2: Participants With CRPC
1
Part 2: Participants With TNBC
0
Part 2: Participants With ER+BC
0
Part 2: Participants With GIST
0
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 2: Participants With NMC
3
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With CRPC
0
Not reported
Not reported
Not reported
Not reported
pH;Week49;n=1,0,1,0,0,0
Analysis denominator · Participants
Group
Source count
Part 2: Participants With NMC
1
Part 2: Participants With SCLC
0
Part 2: Participants With CRPC
1
Part 2: Participants With TNBC
0
Part 2: Participants With ER+BC
0
Part 2: Participants With GIST
0
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 2: Participants With NMC
1
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With CRPC
0
Not reported
Not reported
Not reported
Not reported
pH;Week73;n=1,0,0,0,0,0
Analysis denominator · Participants
Group
Source count
Part 2: Participants With NMC
1
Part 2: Participants With SCLC
0
Part 2: Participants With CRPC
0
Part 2: Participants With TNBC
0
Part 2: Participants With ER+BC
0
Part 2: Participants With GIST
0
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 2: Participants With NMC
1
Not reported
Not reported
Not reported
Not reported
pH;Week85;n=1,0,0,0,0,0
Analysis denominator · Participants
Group
Source count
Part 2: Participants With NMC
1
Part 2: Participants With SCLC
0
Part 2: Participants With CRPC
0
Part 2: Participants With TNBC
0
Part 2: Participants With ER+BC
0
Part 2: Participants With GIST
0
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 2: Participants With NMC
1
Not reported
Not reported
Not reported
Not reported
pH;disc/prog;n=3,6,16,12,12,5
Analysis denominator · Participants
Group
Source count
Part 2: Participants With NMC
3
Part 2: Participants With SCLC
6
Part 2: Participants With CRPC
16
Part 2: Participants With TNBC
12
Part 2: Participants With ER+BC
12
Part 2: Participants With GIST
5
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 2: Participants With NMC
1
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With SCLC
2
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With CRPC
6
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With TNBC
6
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With ER+BC
5
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With GIST
2
Not reported
Not reported
Not reported
Not reported
Protein;Week5;n=8,7,18,12,14,8
Analysis denominator · Participants
Group
Source count
Part 2: Participants With NMC
8
Part 2: Participants With SCLC
7
Part 2: Participants With CRPC
18
Part 2: Participants With TNBC
12
Part 2: Participants With ER+BC
14
Part 2: Participants With GIST
8
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 2: Participants With NMC
1
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With SCLC
1
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With CRPC
9
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With TNBC
3
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With ER+BC
5
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With GIST
6
Not reported
Not reported
Not reported
Not reported
Protein;Week9;n=8,3,12,3,6,5
Analysis denominator · Participants
Group
Source count
Part 2: Participants With NMC
8
Part 2: Participants With SCLC
3
Part 2: Participants With CRPC
12
Part 2: Participants With TNBC
3
Part 2: Participants With ER+BC
6
Part 2: Participants With GIST
5
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 2: Participants With NMC
3
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With SCLC
2
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With CRPC
4
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With TNBC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With ER+BC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With GIST
3
Not reported
Not reported
Not reported
Not reported
Protein;Week13;n=7,2,6,1,2,2
Analysis denominator · Participants
Group
Source count
Part 2: Participants With NMC
7
Part 2: Participants With SCLC
2
Part 2: Participants With CRPC
6
Part 2: Participants With TNBC
1
Part 2: Participants With ER+BC
2
Part 2: Participants With GIST
2
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 2: Participants With NMC
3
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With SCLC
1
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With CRPC
2
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With TNBC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With ER+BC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With GIST
0
Not reported
Not reported
Not reported
Not reported
Protein;Week37;n=1,0,1,0,0,0
Analysis denominator · Participants
Group
Source count
Part 2: Participants With NMC
1
Part 2: Participants With SCLC
0
Part 2: Participants With CRPC
1
Part 2: Participants With TNBC
0
Part 2: Participants With ER+BC
0
Part 2: Participants With GIST
0
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 2: Participants With NMC
1
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With CRPC
0
Not reported
Not reported
Not reported
Not reported
Protein;disc/prog;n=3,6,16,12,12,5
Analysis denominator · Participants
Group
Source count
Part 2: Participants With NMC
3
Part 2: Participants With SCLC
6
Part 2: Participants With CRPC
16
Part 2: Participants With TNBC
12
Part 2: Participants With ER+BC
12
Part 2: Participants With GIST
5
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 2: Participants With NMC
1
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With SCLC
1
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With CRPC
6
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With TNBC
2
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With ER+BC
3
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With GIST
2
Not reported
Not reported
Not reported
Not reported
Erythrocytes;Week5;n=3,3,8,4,4,4
Analysis denominator · Participants
Group
Source count
Part 2: Participants With NMC
3
Part 2: Participants With SCLC
3
Part 2: Participants With CRPC
8
Part 2: Participants With TNBC
4
Part 2: Participants With ER+BC
4
Part 2: Participants With GIST
4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 2: Participants With NMC
2
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With SCLC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With CRPC
5
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With TNBC
2
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With ER+BC
3
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With GIST
2
Not reported
Not reported
Not reported
Not reported
Erythrocytes;Week9;n=4,0,2,2,1,2
Analysis denominator · Participants
Group
Source count
Part 2: Participants With NMC
4
Part 2: Participants With SCLC
0
Part 2: Participants With CRPC
2
Part 2: Participants With TNBC
2
Part 2: Participants With ER+BC
1
Part 2: Participants With GIST
2
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 2: Participants With NMC
2
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With CRPC
1
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With TNBC
1
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With ER+BC
1
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With GIST
1
Not reported
Not reported
Not reported
Not reported
Erythrocytes;Week13;n=3,1,0,0,0,1
Analysis denominator · Participants
Group
Source count
Part 2: Participants With NMC
3
Part 2: Participants With SCLC
1
Part 2: Participants With CRPC
0
Part 2: Participants With TNBC
0
Part 2: Participants With ER+BC
0
Part 2: Participants With GIST
1
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 2: Participants With NMC
3
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With SCLC
1
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With GIST
0
Not reported
Not reported
Not reported
Not reported
Erythrocytes;disc/prog;n=1,2,6,3,4,2
Analysis denominator · Participants
Group
Source count
Part 2: Participants With NMC
1
Part 2: Participants With SCLC
2
Part 2: Participants With CRPC
6
Part 2: Participants With TNBC
3
Part 2: Participants With ER+BC
4
Part 2: Participants With GIST
2
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 2: Participants With NMC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With SCLC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With CRPC
5
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With TNBC
1
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With ER+BC
2
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With GIST
0
Not reported
Not reported
Not reported
Not reported
Specific gravity;Week5;n=8,7,18,12,14,8
Analysis denominator · Participants
Group
Source count
Part 2: Participants With NMC
8
Part 2: Participants With SCLC
7
Part 2: Participants With CRPC
18
Part 2: Participants With TNBC
12
Part 2: Participants With ER+BC
14
Part 2: Participants With GIST
8
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 2: Participants With NMC
4
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With SCLC
4
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With CRPC
2
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With TNBC
5
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With ER+BC
7
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With GIST
2
Not reported
Not reported
Not reported
Not reported
Specific gravity;Week9;n=8,3,12,3,6,5
Analysis denominator · Participants
Group
Source count
Part 2: Participants With NMC
8
Part 2: Participants With SCLC
3
Part 2: Participants With CRPC
12
Part 2: Participants With TNBC
3
Part 2: Participants With ER+BC
6
Part 2: Participants With GIST
5
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 2: Participants With NMC
2
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With SCLC
1
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With CRPC
2
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With TNBC
2
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With ER+BC
5
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With GIST
3
Not reported
Not reported
Not reported
Not reported
Specific gravity;Week13;n=7,2,6,1,2,2
Analysis denominator · Participants
Group
Source count
Part 2: Participants With NMC
7
Part 2: Participants With SCLC
2
Part 2: Participants With CRPC
6
Part 2: Participants With TNBC
1
Part 2: Participants With ER+BC
2
Part 2: Participants With GIST
2
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 2: Participants With NMC
2
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With SCLC
1
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With CRPC
1
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With TNBC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With ER+BC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With GIST
1
Not reported
Not reported
Not reported
Not reported
Specific gravity;disc/prog;n=3,6,16,12,12,5
Analysis denominator · Participants
Group
Source count
Part 2: Participants With NMC
3
Part 2: Participants With SCLC
6
Part 2: Participants With CRPC
16
Part 2: Participants With TNBC
12
Part 2: Participants With ER+BC
12
Part 2: Participants With GIST
5
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 2: Participants With NMC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With SCLC
2
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With CRPC
3
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With TNBC
3
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With ER+BC
5
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With GIST
1
Not reported
Not reported
Not reported
Not reported
Leukocytes;Week5;n=3,3,8,4,4,4
Analysis denominator · Participants
Group
Source count
Part 2: Participants With NMC
3
Part 2: Participants With SCLC
3
Part 2: Participants With CRPC
8
Part 2: Participants With TNBC
4
Part 2: Participants With ER+BC
4
Part 2: Participants With GIST
4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 2: Participants With NMC
1
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With SCLC
1
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With CRPC
5
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With TNBC
3
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With ER+BC
4
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With GIST
4
Not reported
Not reported
Not reported
Not reported
Leukocytes;Week9;n=4,0,2,2,1,3
Analysis denominator · Participants
Group
Source count
Part 2: Participants With NMC
4
Part 2: Participants With SCLC
0
Part 2: Participants With CRPC
2
Part 2: Participants With TNBC
2
Part 2: Participants With ER+BC
1
Part 2: Participants With GIST
3
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 2: Participants With NMC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With CRPC
2
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With TNBC
1
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With ER+BC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With GIST
3
Not reported
Not reported
Not reported
Not reported
Leukocytes;Week13;n=3,1,0,0,0,1
Analysis denominator · Participants
Group
Source count
Part 2: Participants With NMC
3
Part 2: Participants With SCLC
1
Part 2: Participants With CRPC
0
Part 2: Participants With TNBC
0
Part 2: Participants With ER+BC
0
Part 2: Participants With GIST
1
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 2: Participants With NMC
1
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With SCLC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With GIST
0
Not reported
Not reported
Not reported
Not reported
Leukocytes;Week25;n=2,0,1,0,0,0
Analysis denominator · Participants
Group
Source count
Part 2: Participants With NMC
2
Part 2: Participants With SCLC
0
Part 2: Participants With CRPC
1
Part 2: Participants With TNBC
0
Part 2: Participants With ER+BC
0
Part 2: Participants With GIST
0
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 2: Participants With NMC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With CRPC
1
Not reported
Not reported
Not reported
Not reported
Leukocytes;disc/prog;n=1,2,7,3,4,1
Analysis denominator · Participants
Group
Source count
Part 2: Participants With NMC
1
Part 2: Participants With SCLC
2
Part 2: Participants With CRPC
7
Part 2: Participants With TNBC
3
Part 2: Participants With ER+BC
4
Part 2: Participants With GIST
1
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 2: Participants With NMC
0
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With SCLC
1
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With CRPC
2
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With TNBC
3
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With ER+BC
3
Not reported
Not reported
Not reported
Not reported
Part 2: Participants With GIST
1
Not reported
Not reported
Not reported
Not reported
Complete source fields
classes
categories
measurements
group Id
OG001
value
0
group Id
OG002
value
0
group Id
OG003
value
0
group Id
OG004
value
1
denoms
counts
group Id
OG000
value
0
group Id
OG001
value
2
group Id
OG002
value
2
group Id
OG003
value
1
group Id
OG004
value
3
group Id
OG005
value
0
units
Participants
title
Granular cast;Week5;n=0,2,2,1,3,0
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
2
group Id
OG003
value
0
group Id
OG004
value
0
group Id
OG005
value
0
denoms
counts
group Id
OG000
value
1
group Id
OG001
value
2
group Id
OG002
value
6
group Id
OG003
value
3
group Id
OG004
value
4
group Id
OG005
value
0
units
Participants
title
Granular cast;disc/prog;n=1,2,6,3,4,0
categories
measurements
group Id
OG000
value
1
group Id
OG001
value
0
group Id
OG002
value
0
group Id
OG003
value
1
group Id
OG004
value
1
denoms
counts
group Id
OG000
value
1
group Id
OG001
value
2
group Id
OG002
value
2
group Id
OG003
value
2
group Id
OG004
value
4
group Id
OG005
value
0
units
Participants
title
Hyaline cast;Week5;n=1,2,2,2,4,0
categories
measurements
group Id
OG002
value
0
group Id
OG003
value
0
group Id
OG004
value
0
group Id
OG005
value
1
denoms
counts
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
1
group Id
OG003
value
2
group Id
OG004
value
1
group Id
OG005
value
1
units
Participants
title
Hyaline cast;Week9;n=0,0,1,2,1,1
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
1
denoms
counts
group Id
OG000
value
1
group Id
OG001
value
1
group Id
OG002
value
0
group Id
OG003
value
0
group Id
OG004
value
0
group Id
OG005
value
0
units
Participants
title
Hyaline cast;Week13;n=1,1,0,0,0,0
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
2
group Id
OG003
value
0
group Id
OG004
value
0
denoms
counts
group Id
OG000
value
1
group Id
OG001
value
2
group Id
OG002
value
6
group Id
OG003
value
3
group Id
OG004
value
4
group Id
OG005
value
0
units
Participants
title
Hyaline cast;disc/prog;n=1,2,6,3,4,0
categories
measurements
group Id
OG000
value
1
group Id
OG001
value
2
group Id
OG002
value
2
group Id
OG003
value
0
group Id
OG004
value
0
group Id
OG005
value
1
denoms
counts
group Id
OG000
value
8
group Id
OG001
value
7
group Id
OG002
value
18
group Id
OG003
value
12
group Id
OG004
value
14
group Id
OG005
value
8
units
Participants
title
Glucose;Week 5;n=8,7,18,12,14,8
categories
measurements
group Id
OG000
value
2
group Id
OG001
value
1
group Id
OG002
value
0
group Id
OG003
value
0
group Id
OG004
value
0
group Id
OG005
value
0
denoms
counts
group Id
OG000
value
8
group Id
OG001
value
3
group Id
OG002
value
12
group Id
OG003
value
3
group Id
OG004
value
6
group Id
OG005
value
5
units
Participants
title
Glucose;Week9;n=8,3,12,3,6,5
categories
measurements
group Id
OG000
value
2
group Id
OG001
value
1
group Id
OG002
value
1
group Id
OG003
value
0
group Id
OG004
value
0
group Id
OG005
value
0
denoms
counts
group Id
OG000
value
7
group Id
OG001
value
2
group Id
OG002
value
6
group Id
OG003
value
1
group Id
OG004
value
2
group Id
OG005
value
2
units
Participants
title
Glucose;Week13;n=7,2,6,1,2,2
categories
measurements
group Id
OG000
value
1
group Id
OG002
value
0
denoms
counts
group Id
OG000
value
3
group Id
OG001
value
0
group Id
OG002
value
1
group Id
OG003
value
0
group Id
OG004
value
0
group Id
OG005
value
0
units
Participants
title
Glucose;Week37;n=3,0,1,0,0,0
categories
measurements
group Id
OG000
value
1
group Id
OG002
value
0
denoms
counts
group Id
OG000
value
1
group Id
OG001
value
0
group Id
OG002
value
1
group Id
OG003
value
0
group Id
OG004
value
0
group Id
OG005
value
0
units
Participants
title
Glucose;Week49;n=1,0,1,0,0,0
categories
measurements
group Id
OG000
value
1
denoms
counts
group Id
OG000
value
1
group Id
OG001
value
0
group Id
OG002
value
0
group Id
OG003
value
0
group Id
OG004
value
0
group Id
OG005
value
0
units
Participants
title
Glucose;Week73;n=1,0,0,0,0,0
denoms
counts
group Id
OG000
value
12
group Id
OG001
value
14
group Id
OG002
value
23
group Id
OG003
value
19
group Id
OG004
value
21
group Id
OG005
value
13
units
Participants
description
Urine samples were collected for the analysis of following urine parameters: pH, glucose, protein, blood, ketones, specific gravity, erythrocytes and leukocytes. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Only parameters and time points with non-zero values for any increase have been presented.
groups
description
Participants with NUT Midline Carcinoma (NMC) were administered continuous once daily oral dose of 75 mg GSK525762.
id
OG000
title
Part 2: Participants With NMC
description
Participants with small cell lung cancer(SCLC) were administered continuous once daily oral dose of 75 mg GSK525762.
id
OG001
title
Part 2: Participants With SCLC
description
Participants with Castrate-Resistant Prostate Cancer (CRPC) were administered continuous once daily oral dose of 75 mg GSK525762.
id
OG002
title
Part 2: Participants With CRPC
description
Participants with Triple Negative Breast Cancer (TNBC) were administered continuous once daily oral dose of 75 mg GSK525762.
id
OG003
title
Part 2: Participants With TNBC
description
Participants with estrogen receptor positive breast cancer (ER+BC) were administered continuous once daily oral dose of 75 mg GSK525762.
id
OG004
title
Part 2: Participants With ER+BC
description
Participants with Gastrointestinal Stromal Tumor (GIST) were administered continuous once daily oral dose of 75 mg GSK525762.
id
OG005
title
Part 2: Participants With GIST
param Type
COUNT_OF_PARTICIPANTS
population Description
All Treated Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles).
Triangle